Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-Inflammatory Compound
Cynandione A is an acetophenone compound with anti-inflammatory properties. It has been shown to protect hepatocytes and cortical neurons from toxicity, as well as improve neurological deficits in a rat model of cerebral ischemia. Additionally, Cynandione A exerts significant anti-inflammatory effects through the activation of macrophage α7 nAChR and the expression of IL-10, making it a valuable tool for research in neuroprotection and inflammation. -
IL-17 Modulator
IL-17 Modulator 1 disodium is a potent inhibitor targeting the IL-17 signaling pathway. This compound demonstrates significant biological activity in mitigating inflammatory responses, making it valuable for research applications related to autoimmune conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and developing therapies for IL-17 associated diseases. -
Anti-inflammatory Agent
Hydrocortisone hemisuccinate hydrate serves as an orally active glucocorticoid anti-inflammatory agent, primarily targeting and inhibiting pro-inflammatory cytokines such as IL-6 and IL-3 with IC50 values of 6.7 μM and 21.4 μM, respectively. This compound exhibits significant anti-inflammatory and immunomodulatory activities, making it valuable in research applications related to ulcerative colitis and recurrent oral ulcers. Its ability to modulate inflammation positions it as a key reagent for studies in inflammatory disease pathways. -
Anti-inflammatory Agent
4-Ethoxybenzaldehyde is an anti-inflammatory agent that serves as a derivative of benzaldehyde. This compound effectively inhibits the production of key inflammatory mediators, including prostaglandin E2 (PGE2), IL-6, and IL-8, induced by ultraviolet radiation (UVR). Its demonstrated efficacy and safety profile make it valuable for reducing facial redness in topical formulations, notably in oil-in-water emulsions at a concentration of 1%. 4-Ethoxybenzaldehyde is suitable for research on chronic inflammatory skin diseases. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
Anti-IL-17C Antibody
MOR-106 is a humanized anti-IL-17C IgG1 monoclonal antibody that targets interleukin-17C, a cytokine involved in inflammatory responses. By binding specifically to IL-17C, MOR-106 inhibits the NF-κB signaling pathway, demonstrating an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. This reagent effectively reduces skin inflammation and associated inflammatory factors in preclinical models of psoriasis and atopic dermatitis, making it a valuable tool for research into inflammatory skin disorders. -
Anti-inflammatory Agent
Arvelexin is an anti-inflammatory agent that primarily acts by inhibiting NF-κB activation. Isolated from Brassica rapa L. (Brassicaceae), Arvelexin also downregulates the expression of IL-8, making it a valuable compound for research into colonic inflammation. This compound is of interest for studies focused on inflammatory pathways and potential therapeutic applications in inflammatory bowel disease and related disorders. -
IL-17 Modulator
IL-17 Modulator 4 Sulfate targets the IL-17 signaling pathway, functioning as a proagent of IL-17 Modulator 1. This compound exhibits potent modulatory effects on IL-17A, making it a valuable tool for investigating IL-17A mediated diseases. Its applications extend across various fields, including inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes, facilitating a deeper understanding of these conditions. -
CD25 ADC
Camidanlumab tesirine is an antibody-drug conjugate (ADC) that targets CD25, utilizing the HuMax-TAC human IgG1 monoclonal antibody. This compound is conjugated via a cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer, achieving a drug-antibody ratio of 2.3. Camidanlumab tesirine demonstrates exceptional affinity for human CD25 at the picomolar level and exhibits potent cytotoxic effects against various CD25-expressing human lymphoma cell lines, positioning it as a promising candidate for targeted cancer therapies. -
Anti-IL-15RA Antibody
Larnefpendekin alfa is an anti-IL-15RA antibody designed to target and inhibit the interleukin-15 receptor alpha (IL-15RA). This fusion protein plays a pivotal role in modulating immune responses by interfering with IL-15 signaling pathways. Its primary applications include investigations into immune system regulation, potential therapeutic avenues in autoimmune diseases, and cancer immunotherapy. This reagent is valuable for research focused on cytokine interactions and immune cell activation. -
CXCR2 Antagonist
Elubrixin hydrochloride is a potent, selective CXCR2 antagonist that operates as a competitive, reversible inhibitor of the IL-8 receptor. It effectively inhibits neutrophil CD11b upregulation and shape change, with an IC50 of 260.7 nM and 310.5 nM, respectively. This compound is valuable for research applications related to inflammatory diseases, including inflammatory bowel disease and airway inflammation. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
CD31 Agonist
P8RI is a biomimetic peptide that acts as a CD31 agonist. By binding to the juxtamembrane amino acid sequence of the ectodomain of CD31, P8RI restores the CD31 inhibitory pathway, exhibiting significant immunosuppressive effects. This compound is useful for research applications focused on immune modulation and the exploration of CD31-related pathways in cellular processes. -
CXCR4 Antagonist
Burixafor hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4, effectively inhibiting the binding of CXCL12 to the CXCR4 receptor. This compound antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, thereby obstructing the downstream Gαᵢ-mediated inhibition of cAMP signaling. Burixafor hydrobromide is utilized in research for mobilizing CD34+ hematopoietic stem/progenitor cells from the bone marrow to peripheral blood, making it valuable in studies related to autologous hematopoietic stem cell transplantation. -
Oxidative Stress Modulator/Anti-inflammatory Agent
Guluronic acid is an oxidative stress modulator and anti-inflammatory agent. It functions by down-regulating pro-inflammatory genes such as TLR4, NF-κB, and iNOS, while inhibiting COX-2, MMPs, and VEGF activity. This compound promotes the up-regulation of immunoregulatory genes including SHIP1 and SOCS1, thereby mitigating cancer-related inflammation, tumor angiogenesis, cell adhesion, and metastasis, while decreasing immunosuppressive cell accumulation. Guluronic acid has demonstrated potential in extending survival times in tumor-bearing hosts within a non-cytotoxic concentration range and has applications in research related to multiple sclerosis, ankylosing spondylitis, breast cancer, and other inflammatory diseases. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
Anti-VEGFR2/KDR/CD309 Antibody
Girancitug is a humanized IgG1κ monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2/KDR/CD309). It effectively inhibits angiogenesis, making it a valuable tool in cancer research. Girancitug is applicable in anti-angiogenic therapy studies, particularly for cancers such as colorectal and ovarian cancers. -
Anti-inflammatory Agent
L-Ornithine 2-oxoglutarate primarily functions as an anti-inflammatory agent. This compound, a salt of amino acids, exhibits antioxidant properties and plays a role in stimulating insulin and growth hormone production. Additionally, L-Ornithine 2-oxoglutarate enhances intracellular amino acid transport, thereby promoting protein synthesis. It is suited for research applications focusing on metabolic disorders, inflammation, and muscle physiology. -
Anti-Inflammatory Agent
IGF-I (30-41) is a fragment of Insulin-like Growth Factor I comprising amino acids 30 to 41, primarily targeting anti-inflammatory pathways. This peptide exhibits significant biological activities, including anabolic, antioxidant, and cytoprotective effects. It is utilized in research applications aimed at understanding inflammation and related pathophysiological conditions. -
Stable Isotope
Stavudine-d4 is a deuterium-labeled derivative of Stavudine, a potent nucleoside reverse transcriptase inhibitor (NRTI) targeting HIV-1 and HIV-2. This stable isotope is utilized in research applications to study metabolic processes and pharmacokinetics of Stavudine while minimizing background signal from natural isotopes. In addition, Stavudine is known to affect mitochondrial DNA replication, reduce NLRP3 inflammasome activation, modulate Amyloid-β autophagy, and induce apoptosis, making it a valuable tool for investigations into viral pathogenesis and cellular mechanisms. -
COX-2 Inhibitor
COX-2-IN-43 is a selective COX-2 inhibitor with an IC50 of 0.247 μM for COX-2 and 0.983 μM for COX-1. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and colonization while inducing apoptosis. It is valuable for research applications targeting inflammatory diseases and cancer therapeutics. -
iNOS Inhibitor
iNOS-IN-5 (Compound BN-4) is a potent inhibitor of inducible nitric oxide synthase (iNOS) with an IC50 of 0.1707 μM, effectively reducing nitric oxide levels in LPS-induced RAW264.7 cells. This compound demonstrates protective properties against hypoxic injury by decreasing reactive oxygen species (ROS) and lactate dehydrogenase expression, exhibiting significant anti-necrosis and anti-apoptosis effects. Additionally, iNOS-IN-5 has shown neuroprotective activity and protective effects against cerebral ischemia in SD rat models, while also being capable of penetrating the blood-brain barrier. -
STING Inhibitor
STING-IN-16 is a potent inhibitor of the Stimulator of Interferon Genes (STING) pathway, exhibiting IC50 values of 44 nM in human cells and 32 nM in murine cells. It effectively inhibits STING activation, leading to restoration of renal mitochondrial function, reduction of reactive oxygen species (ROS) production, and decreased cell apoptosis. With demonstrated anti-inflammatory efficacy in vivo, STING-IN-16 is valuable for research focused on autoimmune and autoinflammatory diseases. -
CD73 Inhibitor
BK50164 is a selective inhibitor of CD73, exhibiting an IC50 of 13.089 μM. It demonstrates a binding affinity to CD99 with a KD of 1.5 μM. This compound exhibits antiproliferative effects and is capable of inducing apoptosis, as well as causing cell cycle arrest in the Sub-G1 phase. BK50164 is valuable in studies focused on tumor immunology and metabolic regulation. -
Arginase Inhibitor
Nor-NOHA is a selective and reversible inhibitor of arginase, primarily targeting the regulation of arginine metabolism. It has been shown to induce apoptosis in cells expressing arginase 2 under hypoxic conditions and exhibits anti-leukemic activity. This compound is valuable for research applications related to endothelial dysfunction, immunosuppression, and metabolic studies. -
STING Activator
PDIC-NN is a potent STING (Stimulator of Interferon Genes) activator that demonstrates significant anticancer activity. This compound enhances the stability and levels of endogenous cyclic dinucleotides (CDNs), triggering reactive oxygen species (ROS) production and inducing mitochondrial damage. Additionally, PDIC-NN promotes cell apoptosis and inhibits DNA replication while activating the cGAS-STING signaling pathway, thereby augmenting the immunogenicity of tumor cells and eliciting a robust innate immune response. This makes PDIC-NN a valuable tool for studying immune modulation and therapeutic strategies in cancer research. -
CXCR-4 Inhibitor
SSB-2548 is a selective inhibitor of the chemokine receptor CXCR-4. It has demonstrated significant efficacy in inhibiting the proliferation and migration of acute myeloid leukemia cells, while also promoting apoptosis. Its favorable gastrointestinal absorption profile makes SSB-2548 a valuable tool for investigating the underlying mechanisms of leukemia and exploring potential therapeutic interventions. -
COX Inhibitor
Metamizole hemimagnesium is a cyclooxygenase (COX) inhibitor with anti-inflammatory and antioxidant properties. This compound effectively reduces body temperature and has been shown to decrease levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Metamizole hemimagnesium also inhibits cell proliferation and promotes apoptosis. It is utilized in research applications focused on inflammation and fever modulation. -
Nucleoside Reverse Transcriptase Inhibitor
Stavudine sodium is a nucleoside reverse transcriptase inhibitor (NRTI) primarily utilized for its efficacy against HIV-1 and HIV-2. This compound demonstrates the ability to inhibit mitochondrial DNA replication, reduce NLRP3 inflammasome activation, and modulate the autophagy of Amyloid-β, contributing to its therapeutic potential. Additionally, Stavudine sodium is associated with inducing apoptosis in targeted cells, making it a valuable tool in HIV research and related cellular studies. -
R-isomer of Colchicine
(R)-Colchicine is the R-isomer of Colchicine, a potent inhibitor of tubulin polymerization. It exhibits a strong microtubule-disruptive mechanism, with an IC50 value of 3 nM. In addition to its role as a tubulin inhibitor, (R)-Colchicine acts as a competitive antagonist of the α3 glycine receptors, contributing to its diverse biological activities. This compound is significant in research focused on anti-inflammatory responses, immunosuppression, and treatment strategies for gouty arthritis, particularly by mitigating NSAID-induced intestinal injury through NLRP3 inflammasome inhibition. -
PD-1/PD-L Complex Inhibitor
BMS-202 hydrochloride is a potent inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 18 nM and a KD of 8 μM. This nonpeptidic molecule selectively binds to PD-L1, effectively blocking the interaction between human PD-1 and PD-L1. BMS-202 hydrochloride demonstrates significant antitumor activity, making it a valuable tool for research in immunotherapy and cancer biology. -
COX Inhibitor
Ketorolac hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) that acts as a nonselective inhibitor of cyclooxygenase (COX), with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. It is utilized in the study of various ophthalmic conditions, including allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, Ketorolac hydrochloride functions as a DDX3 inhibitor, making it relevant for cancer research applications. -
Stable Isotope
Lenalidomide-d4 is a deuterium-labeled derivative of Lenalidomide, functioning as a stable isotope for advanced chemical research. As an orally active immunomodulator, Lenalidomide targets the cereblon (CRBN) ubiquitin E3 ligase, leading to the selective ubiquitination and degradation of transcription factors IKZF1 and IKZF3. This activity is particularly relevant in the context of mature B-cell lymphomas, including multiple myeloma, where Lenalidomide-d4 has been shown to inhibit tumor growth and promote IL-2 release from T cells. This reagent is suitable for studies in drug mechanisms and development within the field of oncology. -
Stable Isotope
Everolimus-13C2,d4 is a stable isotope-labeled derivative of Everolimus, a potent and selective inhibitor of mTOR1. By binding to FKBP-12, Everolimus forms an immunosuppressive complex that effectively inhibits tumor cell proliferation while promoting apoptosis and autophagy. This compound is valuable for research applications in cancer therapy and immunosuppression studies, facilitating tracking and quantification in metabolic and pharmacokinetic investigations. -
STING Agonist
PDIC-NC is a STING agonist that promotes the activation of the STING pathway, leading to enhanced immune responses against tumors. This compound is cytotoxic to tumor cells and induces reactive oxygen species (ROS) production, as well as apoptosis and autophagy. With its specific distribution to lung tissue, PDIC-NC is particularly valuable for research applications focused on lung cancer. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-11 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 0.21 nM. This compound effectively reduces the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as downregulating the expression of tumor necrosis factor-alpha (TNF-α). By promoting Nrf2 nuclear translocation, Keap1-Nrf2-IN-11 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. -
Anti-inflammatory Agent
Anti-inflammatory agent 64 targets the inhibition of pro-inflammatory cytokines, specifically IL-6 and TNF-α. This compound exhibits both antioxidant and anti-inflammatory activity in vitro and in vivo, making it a valuable tool for studying inflammatory processes. Additionally, it has been shown to significantly reduce paw edema, highlighting its potential utility in therapeutic research for inflammatory diseases. -
Complement factor B synthesis reducer
Agazisiran is a small interfering RNA (siRNA) that targets and reduces the synthesis of complement factor B, a key component in the alternative complement pathway. By modulating complement activation, Agazisiran has potential applications in research focused on autoimmune diseases, inflammatory conditions, and other disorders where complement dysregulation plays a critical role. -
Complement Inhibitor
3-Phenoxybenzaldehyde is a compound identified as a complement inhibitor, exhibiting weak inhibition of the classical pathway of the complement system. This compound demonstrates hemolytic activity, making it relevant for studies related to immune response modulation and complement pathway research. Its applications extend to investigations in autoimmune diseases and therapies targeting complement-mediated cytotoxicity. -
C5 Complement Inhibitor
Avacincaptad pegol is a pegylated RNA aptamer that selectively inhibits complement component C5. By preventing the cleavage of C5 into pro-inflammatory fragments C5a and C5b, this compound mitigates inflammatory cell recruitment and reduces retinal cell damage. Avacincaptad pegol has demonstrated potential in slowing the progression of geographic atrophy (GA) lesions and decreasing the risk of vision loss, making it a valuable tool for research involving age-related macular degeneration (AMD). -
CD11b Agonist
(Z)-Leukadherin-1 is a potent allosteric agonist of CD11b that exhibits oral bioavailability. This compound effectively repolarizes tumor-associated macrophages, diminishes the presence of immunosuppressive myeloid cells within tumors, and enhances the activation of dendritic cells. It serves as a valuable reagent for research in immuno-oncology, exploring mechanisms of immune modulation and macrophage plasticity. -
Complement System Inhibitor
Factor B-IN-1 is an inhibitor of Factor B, targeting the complement system to modulate its activity. This compound demonstrates significant inhibition of the alternative pathway of complement activation, making it a valuable tool for studying complement-mediated diseases and immune responses. Factor B-IN-1 is suitable for use in research applications focused on therapeutic interventions and the development of complement-targeted therapies. -
Anti-complement Activator
Entadamide-A-β-D-glucopyranoside serves as an anti-complement activator, derived from the seeds of Entada phaseoloides. This compound exhibits significant biological activity by inhibiting complement activation, making it a valuable tool for research in immunology and inflammation. Its applications extend to studies focused on understanding the roles of the complement system in various diseases. -
Complement Factor D Inhibitor
Complement Factor D-IN-2 is an inhibitor targeting complement factor D, effectively interrupting the complement cascade at a critical juncture within the alternative complement pathway. By inhibiting factor D, this compound presents valuable opportunities for investigating the role of complement activation in autoimmune diseases. Researchers can utilize Complement Factor D-IN-2 to explore therapeutic strategies aimed at modulating immune responses and mitigating the progression of complement-mediated pathologies. -
Pro-Inflammatory Peptide
C5a Anaphylatoxin (human) is a pro-inflammatory peptide that functions as a potent leukocyte chemoattractant. It plays a significant role in mediating inflammatory responses and can be employed in research related to various immune system disorders, including allergic asthma. This reagent is ideal for studies investigating the mechanisms of inflammation and the effects of immune modulation.
